Biomea Fusion マネジメント

マネジメント基準チェック /14

Biomea Fusionの CEO はThomas Butlerで、 Aug2017年に任命され、の在任期間は 7.25年です。の年間総報酬は$ 2.71Mで、 22.5%給与と77.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.88%を直接所有しており、その価値は$ 17.18M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と2.9年です。

主要情報

Thomas Butler

最高経営責任者

US$2.7m

報酬総額

CEO給与比率	22.5%
CEO在任期間	7.3yrs
CEOの所有権	6.9%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

CEO報酬分析

Biomea Fusion の収益と比較して、Thomas Butler の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$144m
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$127m
Dec 31 2023	US$3m	US$609k	-US$117m
Sep 30 2023	n/a	n/a	-US$108m
Jun 30 2023	n/a	n/a	-US$102m
Mar 31 2023	n/a	n/a	-US$95m
Dec 31 2022	US$921k	US$583k	-US$82m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$7m	US$552k	-US$42m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$2m	US$229k	-US$5m

報酬と市場: Thomasの総報酬 ($USD 2.71M ) は、 US市場 ($USD 1.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Thomasの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Thomas Butler (43 yo)

7.3yrs

在職期間

US$2,707,310

報酬

Mr. Thomas Butler co-founded Biomea Fusion, Inc in August 2017 and has been its Chief Executive Officer and Director since August 2017. He serves as the Chairman of Biomea Fusion, Inc. He serves as a Manag...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thomas Butler	Co-Founder	7.3yrs	US$2.71m	6.88% $ 17.2m
Ramses Erdtmann	Co-Founder	7.3yrs	データなし	5.66% $ 14.1m
Franco Valle	CFO & Principal Accounting Officer	3.3yrs	US$1.30m	0.12% $ 292.8k
Juan Frias	Chief Medical Officer	1.3yrs	US$4.17m	0.00096% $ 2.4k
Heow Tan	Chief Technology & Quality Officer	4yrs	データなし	データなし
Naomi Cretcher	Chief People Officer	no data	データなし	データなし
Thorsten Kirschberg	Executive Vice President of Chemistry	4.2yrs	データなし	データなし
Stephan Morris	Chief Development Officer	2.8yrs	データなし	データなし
Ravi Upasani	Executive Vice President of Intellectual Property	3.6yrs	データなし	データなし
Caroline Perez- Dupont	Senior Vice President of Contracts	less than a year	データなし	データなし

3.6yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: BMEAの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Butler	Co-Founder	7.3yrs	US$2.71m	6.88% $ 17.2m
Ramses Erdtmann	Co-Founder	7.3yrs	データなし	5.66% $ 14.1m
Eric Aguiar	Independent Lead Director	3.9yrs	US$254.80k	0% $ 0
Juliana Chan	Member of Scientific Advisory Board	less than a year	データなし	データなし
Elizabeth Faust	Independent Director	2.4yrs	US$221.99k	0% $ 0
Bihua Chen	Independent Director	3.9yrs	US$228.80k	0% $ 0
Sumita Ray	Independent Director	3.4yrs	US$235.30k	0% $ 0
Julio Rosenstock	Member of Scientific Advisory Board	less than a year	データなし	データなし
Michael J. Hitchcock	Independent Director	3.7yrs	US$241.30k	0.041% $ 103.3k
Jeremy Pettus	Member of Scientific Advisory Board	less than a year	データなし	データなし
Rohit Kulkarni	Member of Scientific Advisory Board	less than a year	データなし	データなし
Freddy Eliaschewitz	Member of Scientific Advisory Board	less than a year	データなし	データなし

2.9yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: BMEAの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Biomea Fusion マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Recent updates

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022

Biomea Fusion, Inc. Appoints Steve Morris, M.D. as Chief Medical Officer

マネジメント基準チェック /14